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1. Introduction  
Many soy supplements in the market focus on estrogen and antioxidant properties of 
isoflavonoid, genistein. Due to the structural similarity to estrogen and binding to estrogen 
receptor, genistein is often referred to as a phyto-hormone or a dietary estrogen from soy. 
Target applications of isoflavone-enriched whole soy concentrates include natural hormonal 
replacement therapy and women’s health products (Knight & Eden, 1996; Messina, 1995). 
However, beneficial effect of genistein on human health extends to the prevention of cancer, 
cardiovascular events, diabetes, and incidence of inflammatory diseases and management of 
some metabolic diseases (Birt et al., 2001, Kurzer, 2002; Rimbach et al., 2008; Węgrzyn et al., 
2010).  
The view of genistein as a safe and healthy food supplement is not entirely clear, however. 
Although most studies show no risk of high consumption of soy-based products for human 
growth, development or reproduction, there are some data urging caution in genistein 
overdose. Genistein is implicated as a possible cause of infertility and liver disease in some 
animal species. Consumption of genistein-rich food and supplements during pregnancy 
have been suggested to increase the risk of infant leukemias (Hengstler et al., 2002). In 
addition, experimental data showing stimulatory effect of genistein on proliferation of some 
breast cancer cells lines raise the problem of safety of genistein supplementation in women 
with diagnosed breast cancer (Lavigne et al., 2008).  
Despite the controversies about safety and benefits of soy food supplementation, the 
pleiotropic activity of genistein, resulting from its interaction with numerous molecular 
targets, along with the possibility of chemical derivatization of a molecule place genistein 
among leading compounds for drug development.  
This chapter deals with two main issues: (1) describes the main molecular targets affected by 
genistein and indicates alterations in signaling pathways, revealed by global gene profiling 
analyses, and (2) delineates the relevant examples of genistein derivatives synthesized with 
aim to obtain compounds exhibiting improved pharmacological activity, increased affinity 
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to molecular targets or altered mode of action as compared to the parent drug. The clinical 
utility of genistein-based pharmaceuticals is also discussed. 
2. Molecular targets affected by genistein  
Genistein is known for its pleiotropic effects, mediated by alteration of the activity of key 
enzymes involved in cell signaling, and by changes of the expression of the genes involved 
in various physiological processes. To the large group of genistein targets new proteins 
discovered with use of potent computational methods have joined recently. The interplay 
between different signaling pathways is extensively studied; however, exact molecular 
mechanisms have not been clearly defined yet. 
2.1 Binding of genistein to different proteins 
The proteins affected directly by genistein belong to many families. Among them are 
nuclear receptors, tyrosine-specific protein kinases, topoisomerases, ABC transporters and 
transport proteins present in the bloodstream (Tab. 1).  
Nuclear receptors are members of a large family of transcription factors activated by 
binding of a ligand and regulating gene expression underlying a plethora of physiological 
and pathological states. Genistein binds to and activates estrogen receptors, peroxisome-
proliferators activated receptors, liver X receptors and estrogen related receptors.  
It was recognized very early that the chemical structure of genistein bears strong similarity 
to 17ǃ-estradiol, and that genisten binds to estrogen receptors (ER) and to sex hormone-
binding globulins (Klinge, 2000; Kuiper et al., 1998; Kurzer, 2002). A functional interaction of 
genistein with estrogen receptors, leading to stimulation of ER responsive genes was 
confirmed in experiments in vitro (Birt et al., 2001; Kostelac et al., 2003). There are two 
isoforms of estrogen receptor, ERǂ and ER, differentially expressed in tissues and 
exhibiting different biological functions. The hydrophobic ligand-binding cavity displays 
53% of similarity between two isoforms (Manas et al., 2004). This pocket contains 12 ǂ-
helices and two -sheets, connected by several short straight fragments. Inside a ligand 
binding cavity the ligand molecule is oriented with hydrogen bonding at the ends and 
hydrophobic van der Waals contacts along the body of the hormone. In the ERǂ functionally 
important polar amino acids in the binding pocket include: Glu-353, Arg-394, and His-524 
(Tanenbaum et al., 1998). These aminoacids interact with 7 and 4’ OH groups of genistein. 
Several other amino acid residues create hydrophobic bonds essential for stabilizing the 
nonpolar elements of the ligand ring structure. Genistein is regarded as an agonist of ERǂ. 
Although ligand binding domain sequence and structure in ER is very similar to ERǂ and 
stabilization of a ligand occurs due to analogous hydrogen bonding with the side chains of 
Glu-305, Arg-346 and His-475 (Fig. 1), genistein binds to this form with higher affinity than 
to ERǂ (Manas et al., 2004). The position of the ligand in both receptor types is similar, but 
the volume of a cavity is smaller in ER, and genistein is bound more tightly in the cavity. 
Despite the higher affinity to ER than ERǂ, genistein is only partial agonist of ER. The 
explanation may be derived from the different conformations of a ligand-bound state of ERǂ 
and ER. Hormone-dependent activation of a receptor is a result of the movement of helix 
12 from one position to another. The positional variability of this substructure appears to be 
a critical attribute of the ER receptors in their variable response to different ligands (Pike et 
al., 1999). 
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Recently it was shown that proteins constituting the family of estrogen related receptors 
(ERRs) are also able to bind genistein (Suetsugi et al., 2003). Although they display 
similarity to estrogen receptors, they do not bind estrogens. ERRs are referred to as orphan 
receptors, because no endogenous ligands required for their activity have been identified so 
far. The ligand-binding pockets of ERRs are very small (about half size of ERǂ) and partially 
filled with the aromatic bulky side chains of aminoacids forming the cavity, what is 
supposed to mimick the ligand-bound state inducing constitutive activity of the receptor. 
Surprisingly, genistein is a strong agonist of those receptors, augmenting their basal activity. 
Docking results showed that genistein, due to the small size of the cavity, is tightly packed 
and deeply docked into the ligand-binding site (Suetsugi et al., 2003) (Fig. 2).  
 
 
Fig. 1. The ligand-binding cavity in the genistein bound human estrogen receptor . 4’OH 
group of genistein forms hydrogen bonds with the Glu-305, the Arg-346 and a water 
molecule; 7OH group forms hydrogen bond with His-475. Reprinted by permission from 
Macmillan Publishers Ltd: Pike et al. 1999, EMBO Journal Vol.18, No.17, 4608–4618, 
Copyright 1999. 
 
 
Fig. 2. The binding pocket of genistein-bound ERRǂ. 7OH group of genistein forms 
hydrogen bonds with the glutamate in helix 3, the arginine in helix 5, and a water molecule;  
4’OH group forms hydrogen bond with H398. Adapted and reprinted by permission from 
American Association for Cancer Research, Suetsugi et al. 2003, Molecular Cancer Research 
Vol.1, No.13, 981-991. 
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Other members of nuclear receptor family activated by genistein are peroxisome proliferators-
activated receptor  (PPAR) (Dang et al., 2003) and PPARǂ (Kim et al., 2004; Kim et al., 2005). 
The main role of PPAR is to control the genes involved in adipocyte differentiation and lipid 
storage. The structure of ligand binding domain in the PPAR is similar to both PPARǂ and 
PPAR, and consists of 12 helices arranged in an antiparallel helix sandwich, and additional 3-
stranded antiparallel  sheet (Cronet et al., 2001). Docking studies, supported by the functional 
assay, characterized genistein as a full PPAR agonist (Salam et al., 2008). Subsequent studies 
shown, that agonistic action of genistein on PPAR stimulates adipogenesis (Relic et al., 2009). 
It is worth to keep in mind that genistein concurrently activates two different transcriptional 
factors, ERs and PPARǄ, which have opposite effects on osteogenesis or adipogenesis. Thus, 
genistein as an agonist of both receptors may affect the balance between activated ERs and 
PPARǄ, which determines the final effects on osteogenesis and adipogenesis.  
Very weak binding of genistein to androgen receptor (AR) was reported by Bectic et al. 
(2004). However, the inhibition of specific androgen binding was less than 25% at 1000-fold 
higher concentration of genistein (1 M) in a radioligand-binding assay. Moreover, this 
weak binding did not influenced AR transcriptional activity measured by a reporter gene 
assay in PC-3 and DU 145 cells. The authors concluded, that genistein influence the 
expression of AR dependent genes indirectly, by down-regulation of AR.  
Another group of enzymes binding genistein are proteins, which share in their structure the 
consensus sequence for ATP binding, such as tyrosine kinesis, topoisomerases, ABC 
transporters, and ion channels. Although genistein does not resemble ATP, its binding is 
competitive to ATP.  
Historically, the first proteins affected by genistein were protein tyrosine kinases (PTK) 
(Akiyama et al., 1987). Suppression of PTKs is thought to occur due to genistein binding 
with a common, highly conservative sequence at, or near to, the ATP-binding domain 
(Markovits et al., 1989; Akiyama et al., 1987). Genistein is a competitive inhibitor of ATP in a 
number of tyrosine kinases that utilize the G-X-G-X-X-G consensus for ATP binding 
(Akiyama et al., 1987).  
To another group of proteins affected by genistein belong hexose transporters. The 12 
transmembrane ǂ-helical domains of the monomeric GLUT protein form a central water-
filled pore, facilitating glucose transport. Vera et al. (1996) found that genistein inhibited 
transport of substrates by the GLUT1, blocking its ATP-binding domains. Similar 
mechanism of glucose uptake inhibition by genistein occurs in GLUT4 (Bazuine et al., 2005). 
Exact binding mode of genistein in GLUT1 is not known. It is hypothesized, that genistein, 
binding to the cytoplasmic surface of GLUT1, uses the sequences of close homologies to the 
sequences in the ligand-binding cavity of estrogen receptors (Afzal et al., 2002) (Fig. 3). 
These domains are in close vicinity or partially overlap the ATP-binding sites, so binding of 
estrogen, tamoxifen and genistein may competitively inhibit ATP binding. 
The inhibition of topoisomerases by genistein is thought to be mediated by its binding to N-
terminal ATP-binding motif. Topoisomerase II maintains the integrity of the cleaved DNA 
by forming covalent bonds with each newly created 5’-phosphate termini of the cleaved 
DNA segment. This transfer of phosphodiester bonds from DNA to topoisomerase II is 
similar to the autophosphorylation reaction of tyrosine kinases, where the enzyme forms a 
bond between its tyrosine and the phosphate group of ATP. Eucaryotic topoisomerase IIǂ 
has two consensus ATP-binding motifs. Only Walker A site (residues 161-166 in human 
topoisomerase IIǂ) is utilized for ATP binding in the eukaryotic type II enzyme. The Walker 
B site (residues 472-477), located near the region of the enzyme, in close proximity to the site 
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of DNA cleavage and ligation, has no known function for topoisomerase activity, but its 
consensus sequence (G-X-G-X-X-G), is the same, as the ATP-binding consensus sequence in 
a number of tyrosine kinases (Markowitz et al., 1989). Probably, this non-functional 
consensus site, common with protein kinases is the sequence of topoisomerase IIǂ, which 
binds genistein (Bandele &Osheroff 2007).  
 
 
Fig. 3. Structure of GLUT1. A. Two-dimensional model of GLUT1 with Walker ATP-binding 
domains (red), and homologies to ER (turquoise, violet, blue and yellow). B. Close view of 
H bonding interactions of genistein (dark red) with His and Arg of GLUT1. Colours on A 
and B match each other. Reproduced with permission, from Afzal et al. 2002, Biochemical 
Journal Vol. 365, No.3, 1707-1719, © the Biochemical Society. 
Cystic fibrosis transmembrane conductance regulator (CFTR) belongs to ABC transporter-
class ion channels, and transports chloride through epithelial cells membranes. Potentiation of 
Cl2- ion efflux through CFTR by genistein is thought to result from interaction of the 
isoflavonoid with one of two ATP-binding sites in the regulatory nucleotide-binding 
domains (NBD) of a protein. In CFTR, the membrane spanning domains form a pathway for 
passive anion flow that is gated by cycles of ATP binding and hydrolysis (Hwang & 
Sheppard 2009) (Fig. 4). It is established that ATP hydrolysis at ATP-binding site 2 is 
responsible for a rapid closure of the gate opened by ATP (Chen & Hwang, 2008; Gadsby et 
al., 2006). Competitive binding of genistein to the second ATP-binding site disables channel 
gating (Wang et al., 1998), what means that potentiation of CFTR Cl- current is a result of the 
channel locking by genistein in a stable open state. Exact mode of genistein binding to CFTR 
is unknown, however docking studies indicate several putative binding sites in the protein 
(Huang et al, 2009) (Fig. 4B). 
The next group of proteins binding genistein are blood proteins. Binding of genistein to 
human sex hormone-binding proteins (hSHBG) is reversible and competitive for both 
[3H]testosterone and [3H]17b-estradiol (Dechaud et al., 1999). Genisten binding to hSHBG 
may influence its bioavailability to cell tissues, and displace endogenous sex steroid 
hormones from hSHBG binding sites.  
Human serum albumin (HSA) with high affinity binding sites is a major transporter for 
delivering several endogenous compounds and drugs in vivo. Structural analysis showed 
that genistein binds to HSA via polypeptide polar groups (Mandeville et al., 2009). Binding 
of genistein to albumins is reversible, rapid and the concentration of unbound isoflavone is 
in an equilibrium state. 
It is worth to note, that hemoglobin is able to bind genistein, what makes this most 
abundant protein of blood, important for genistein transportation, distribution and storage 
(Yuan et al., 2008).  
Transthyretin (TTR) is a tetrameric -sheet-rich transporter protein involved to some extent 
in the transport of thyroid hormone, thyroxine. TTR binds genistein via the thyroxine (T4) 
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binding sites. TTR has two identical funnel-shaped thyroxine-binding sites located at the 
dimer–dimer interface (Fig. 5). Binding of thyroxine stabilizes native, tetrameric state, 
whereas dissociation of the hormone promotes dissociation of the protein to monomers, and 
their abnormal aggregation, observed in human amyloid diseases. Since only 1% of TTR is 
bound to thyroxine, small molecules, such as genistein may help to stabilize the tetrameric 
structure. Genistein is known to potently inhibit TTR amyloid fibril formation (Green et al., 
2005). In TTR, the mode of genistein binding is sequential, with negative cooperativity 
observed. Binding of the first genistein molecule to TTR generates allosteric adjustment of 
conformation in the second genistein binding site. The most stable conformation of TTR 
protein is observed when two molecules of genistein are bound to the tetramer (Trivella et 
al., 2010).  
 
 
Fig. 4. The simplified model of CFTR Cl− channel opening. A. closed state, B. open state, C. 
stable open state, forced by genistein (dark blue molecule), which blocks ATP-binding site 2. 
IN and OUT denote the intra- and extracellular sides of the membrane, respectively. NBD1 – 
turquoise, NBD2 – green, site 1 and site 2 – ATP-binding sites. D. A stereo view of five 
putative binding sites of genistein to human CFTR. Ball-and-stick molecules of genistein are 
shown in blue, and the ATP in yellow. Residues are important for interacting with genistein 
are in magenta. A and B - Reproduced with permission from John Wiley and Sons, Hwang 
& Sheppard 2009, Journal of Physiology, Vol.587, No.10, 2151–2161, D - Reprinted from 
Journal of Molecular Graphics and Modelling, Vol.27, No. 7, Huang et al. 2009, Pages 822-
828, Copyright (2009), with permission from Elsevier. 
 
 
Fig. 5. Structure of transthyretin. A. Schematic representation of the tetrameric structure of 
TTR depicting the two thyroxine-binding sites with two molecules of genistein stabilizing 
the tetramer. Modified from Green et al., 2005, with permission. Copyright (2005) National 
Academy of Sciences, U.S.A. 
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There are also many intracellular proteins which functions are affected upon genistein binding 
listed in the Tab. 1., which does not fit any group described above, such as ornithyne 
decarboxylase, aromatase CYP19 or tubulin. Cytoskeleton protein, tubulin binds genistein at 
ANS-binding site, what leads to depolymerization of  microtubules (Mukherjee et al., 2010).  
 
Classess of 
proteins binding 
genistein  
Proteins Type of 
influence on a 
protein activity 
Binding affinity  
(Ki) or 50 % 
inhibitory 
concentration 
(IC50) 
Source 
Estrogen 
receptors 
Erǂ Agonist Ki=370 nM 
IC50=1.97-14 M 
Matsuda et al., 2001, 
Güngör et al., 2006, 
Kostelac et al., 2003 
ER Partial agonist Ki=24nM; 
IC50=1.3-395 nM 
Pike et al., 1999,  
Matsuda et al., 2001, 
Chesworth et al., 2005; 
Mewshaw et al., 2007  
Estrogen related 
receptors 
ERRǂ Agonist IC50=2.4 M Suetsugi et al., 2003 
ERR Agonist IC50>10 M Suetsugi et al., 2003 
ERR Agonist IC50>10 M Suetsugi et al., 2003 
Peroxisome 
proliferator 
activator receptor 
PPAR Agonist Ki=5.7 M 
IC50=16.7 M 
Dang et al., 2003, 
Salam et al., 2008 
Androgen 
receptor 
AR No 
transcription 
activation 
Ki>>1 M Bektic et al., 2004 
Liver X receptor  LXR-ǂ Agonist IC50=31 M Dodo et al., 2008 
LXR- Agonist IC50=22 M Dodo et al., 2008 
Tyrosine kinases EGFR Inhibitor IC50=22 M Akiyama et al., 1987 
Pp60 v-src Inhibitor IC50=26 M Akiyama et al., 1987 
Pp110  
gag-fes 
Inhibitor IC50=24 M Akiyama et al., 1987 
MEK4 Inhibitor IC50=0.4 M Xu et al., 2009 
ABL Inhibitor IC50=10 M Traxler et al., 1995 
Protein 
kinase C 
Inhibitor IC50=15 M Traxler et al., 1995 
Tyrosine 
Kinase Syk 
Inhibitor IC50=39 M Xie et al, 2009 
FGF receptor 1 FGF1 Inhibitor IC50<25 M Rao, 1997 
Ion channels CFTR Potentiator Ki=1.8 M Melani et al., 2010 
www.intechopen.com
 Soybean and Health 
 
260 
Classess of 
proteins binding 
genistein  
Proteins Type of 
influence on a 
protein activity 
Binding affinity  
(Ki) or 50 % 
inhibitory 
concentration 
(IC50) 
Source 
Glucose 
transporters 
GLUT1 Inhibitor Ki=4-12 M Afzal et al., 2002;  
Vera et al. 1996  
GLUT4 Inhibitor IC50=20 M Bazuine et al., 2005 
MDR proteins ABC G2 Substrate n.a. Imai et al., 2004; 
 Zhang et al., 2004;  
Perez et al., 2009 
Topoisomerase I Topo I Inhibitor n.a. Okura et al., 1988 
Topoisomerase II Topo II  Inhibitor IC50<30 M Bandele & Osheroff, 2007 
Topo II  Inhibitor IC50=30 M Constantinou et al., 1995; 
Okura et al., 1988; 
Markovitz et al., 1989  
Bacterial 
gyrase 
Inhibitor IC50>200 M Bernard et al., 1997 
Bacterial 
topo IV 
Inhibitor IC50=93 M Bernard et al., 1997 
Adenosine 
receptors 
A1 Inhibitor IC50=2.6 M Schulte & Fredholm, 2002 
A2A Inhibitor IC50=15.3 M Schulte & Fredholm, 2002 
Aromatase  Cyp 19 Inhibitor Ki=100 M Paoletta et al., 2008 
Tubulin  Tubulin Polymeriza-
tion inhibitor 
Ki=20 M IC50>87 
M 
Mukherjee et al., 2010 
Ornithine 
decarboxylase 
ODC Inhibitor >10 M Fang & Cassida, 1999 
Sex hormone-
binding globulin 
hSHBG Competitive 
binding to 
testosterone 
and estradiol 
Ka=1.7x105 M−1 
(Testosterone)  
Ka=6.3 x105 M−1 
(estradiol) 
Dechaud et al.,1999 
Albumins HAS  K=2.4×104 M−1 Mandeville et al., 2009 ; 
Bian et al. 2004   
Haemoglobin   n.a.  Yuan et al., 2008 
Transthyretin TTR Competitor of 
T4 
Ki=70nM Radovic et al., 2006  
Stabilisator of a 
tetramer 
Kd1=40 nM, 
Kd2=1.4 M 
Green et al., 2005  
 
 
Table 1. Proteins binding genistein and the type of influence on their activity  
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New efficient computer-assisted methods facilitate rapid identification of protein targets of 
potential drugs (Chen et al., 2003). INVDOCK is one of in silico techniques specifically 
applied to identification targets of medicinal plants ingredients and synthetic chemicals. It is 
based on ligand–protein inverse docking of a tested ligand to known ligand-binding pockets 
of the proteins from a 3D structural database. Many proteins indicated by the aid of 
INVDOCK as potential targets of genistein were previously confirmed or implicated by 
experiments. This approach allowed also indication of multiple new targets with therapeutic 
implications, able to bind genistein. Among them are: thymidylate synthetase, purine 
nucleoside phosphorylase, cyclophilin A, farnesyltransferase, guanylyl cyclase, carbonic 
anhydrase (cancer treatment), DNA polymerase, (cancer and Herpes viral infection), inosine 
dehydrogenase, purine nucleoside phosphorylase (Malaria), dihydrofolate reductase 
(leprosy), phospholipase A2 (inflammation), carbonic anhydrase I (hypertension and 
glaucoma), protein kinase C (cardiovascular disease).  
From many studies on the oral bioavailability of genistein it is clear that in vivo plasma 
concentrations of genistein is 0.1–8 M at a dose of 16 mg/kg of body weight (Bloedon et al., 
2002; Setchell et al., 2001). Tab. 1. shows that the concentration of genistein, inhibiting or 
stimulating several potential targets, is much higher than its concentration in plasma, thus 
its physiological relevance is disputable. However, it might be possible, that under chronic 
exposure, even weak effects of genistein on molecular targets influence the overall 
physiological status.  
2.2 Signalling pathways influenced by genistein in microarrays profiling  
Specific changes in gene expression profiles brought about by the genistein treatment can 
occur either due to direct influence of the flavonoid on activity of transcription factors or to 
indirect compensatory homeostatic mechanisms. A global analysis of gene expression in 
response to a plejotropic compound, such as genistein, in models of different organs under 
physiologic and disease conditions appears to be essential for understanding the molecular 
mechanisms of genistein action and seems to be advantageous approach in comparison to 
“gene-by-gene” studies. In this chapter we summarize the most important observations 
derived from transcryptomic, microarray-based studies aimed to identify gene sets 
influenced by genistein in normal and tumor tissues.  
In general, microarray data published so far supports existing hypotheses on the 
mechanisms of action of genistein, both beneficial for human health (i.e. reduction of cancer 
risk, amelioration of postmenopausal syndrome and decrease of bone resorption in 
postmenopausal women, lipid metabolism, cardiovascular homeostasis) (Kim et al., 2005; 
Lee et al., 2007; Pie et al, 2006; Rice et al., 2007) and unfavorable (as estrogen-dependent  
cancer cell proliferation and adverse effects on the reproductive organs or involution of 
thymus and auto-immune disorders) (Lee et al., 2007; Naciff et al., 2002; Selvaraj et al., 2005). 
Those homeostasis-maintaining or homeostasis-affecting effects are often observed at low 
concentrations of genistein, essentially not exceeding 5 M.  
Functional categorization of genes affected by genistein on transcriptional level repeatedly 
indicates genes involved in cell growth, cell cycle, apoptosis, cell signals transduction, 
angiogenesis, tumor cell invasion and metastasis, cholesterol synthesis and lipid metabolism 
(Kim et al. 2005; Li et al., 2004; Li & Sarkar, 2002; Niculescu et al., 2007; Pie et al., 2006; Rice 
et al., 2007; Selvaraj et al., 2005). Among the genes regulated by genistein is a group of genes 
with common mechanism of regulation by nuclear receptors: estrogen receptors (Selvaraj et 
al., 2005) and androgen receptor (Rice et al., 2007).  
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The papers comparing the expression profiles of cells treated with estradiol and genistein 
show a considerable overlap in the genes not only in reproductive organs, but also in other 
tissues influenced by estrogens. Among non-reproductive organs in which strong changes 
of expression profile occurred in estrogen receptor-dependent manner after treatment with 
genistein are bones (Pie et al., 2006), liver and adipose tissue (Kim et al., 2005), thymus 
(Selvaraj et al., 2005), lymphocytes (Niculescu et al., 2007), brain (Lyou et al, 2002), 
endothelial cells (Rimbach et al., 2008), cardiovascular system and muscles (Velders et al., 
2010). It has to be noted that the expression profile influenced by high genistein uptake may 
not depend on genistein directly, but on the ability of individuals to metabolize genistein to 
equol (Niculescu et al., 2007). 
The findings that dietary isoflavones may play a beneficial role in lipid and carbohydrate 
metabolism prompted the group of Kim et al. (2005) to perform cDNA microarray-based 
analysis in mice fed with high-fat diet (HFD) and supplemented with genistein. Mice fed the 
high-fat diet had abnormal lipid profiles, significantly greater body weight, and visceral fat 
accumulation and all these effects had been significantly reduced by genistein 
supplementation. Of much importance was also the observation that the expression of 84 
genes affected by the high fat diet was normalized by genistein. The expression of genes 
encoding enzymes of cholesterol biosynthesis, which decreased by at least 50% in the high 
fat diet fed mice, returned to normal level as a result of genistein supplementation. 
Pie et al. (2006) in their cDNA microarray study shown changes in the expression levels of 
bone metabolism-related genes, including those encoding calciotropic receptor, cytokines, 
growth factors and bone matrix proteins by genistein in ovariectomized mice. The study 
demonstrated that genistein prevented bone loss caused by estrogen deficiency without 
substantially affecting the uterus. 
Many studies have correlated the soy-rich diet with a decreased risk of developing 
hormone-dependent cancers, including breast and prostate cancer. The result of a study 
carried on HCC1395 cells line derived from an early-stage primary breast cancer showed 
that genistein dose-dependently decreased cell viability and inhibited the invasion potential 
(Lee et al., 2007). The gene expression profile revealed upregulation of some genes which 
inhibit invasion and metastasis and downregulation of genes promoting these processes, 
indicating that genistein-induced alternations of gene expression involving metastasis may 
be exploited for setting up chemopreventive and therapeutic strategies, particularly for 
early-stage breast cancer.  
The oligo-microarray study by Lavigne et al. (2008) performed on MCF-F breast cancer cells 
shown that at physiologic concentration (1 or 5 M) genistein elicited an expression pattern 
suggestive of increased mitogenic activity, and at pharmacological level (25 M) it induced a 
pattern that likely contributes to increased apoptosis, decreased proliferation and decreased 
total cell number. These results strength former observations of biphasic response of certain 
cell lines to genistein.  
Genistein is also a candidate prostate cancer preventive phytochemical. DNA microarray 
approach to examine the effects of genistein at concentrations within its physiologic range 
on global gene expression patterns in androgen-responsive cancer cells shown a 
concentration-dependent modulation of multiple cellular pathways that are important in 
prostate carcinogenesis. Interestingly, the androgen receptor (AR)-mediated pathways, in 
particular, appeared to be modulated by genistein at low concentrations. The regulation of 
AR-mediated pathways is potentially the most relevant chemopreventive mechanism for 
genistein administered at physiologic levels (Rice et al., 2007; Takahashi et al., 2004).  
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Selvaraj et al. (2005) gained insight into signaling pathways that regulate various stages of 
thymocyte maturation, dependent on estradiol and genistein, and found that the effects of 
both compounds were similar, although, genistein down regulated more genes than 
estradiol. Genistein was also shown to induce genes involved in apoptosis, which is a 
continuous process in the thymus undergoing active thymocyte selection, but at the same 
time it affected genes which may facilitate thymic release of autoimmune cells.  
Microarrays were also used to get closer insight into the influence of genistein on female 
reproductive organs. The study performed by Naciff et al. (2002) revealed that prenatal 
exposure to genistein altered the fetal gene-expression pattern of the rat uterus and ovaries 
in a similar manner as exposition to the estrogenic compounds, such as 17-ethynylestradiol 
and bisphenol A. Toxicogenomic analysis with use of cDNA microarray applied to 
determination of testicular mRNA profiles was proposed as a useful tool for evaluation of 
delayed long-term effects after fetal or neonatal exposure of mice to genistein (Adachi et al., 
2004). Although no morphological changes in the testes of genistein-treated mouse were 
observed, the authors indicated the gene (GeneBank accession No. W49392), which might be 
useful biological marker, in addition to ERǂ and AR, for predicting the effects of neonatal 
exposure to genistein or related compounds.  
The long lasting effects of genistein may result from epigenetic influence of genistein on 
gene expression. The use of differential methylation hybridization (DMH) arrays for 
screening of the changes in the methylation status of the cytosine guanine dinucleotide 
(CpG) islands in the mouse genome shown important genistein–induced alterations (Day et 
al., 2002). The study shown that changes in the methylation pattern reflected potential of 
genistein for preventing the development of certain prostate and mammary cancers by 
maintaining a protective DNA methylation profile (Day et al., 2002). The ability of genistein 
to change the methylation status was observed in several other studies. Genistein was 
shown to partially demethylate the promoter of the GSTP1 tumor suppressor gene in MDA-
MB-468 breast cancer line (King-Batoon et al., 2008). Another study shown the change of 
methylation status in mice prenatally exposed to genistein (Vanhees et al., 2011). Genistein 
exposure was associated with hypermethylation of certain repetitive elements, what 
coincided with a significant down-regulation of estrogen-responsive genes and genes 
involved in hematopoiesis in bone marrow cells of genistein-exposed mice.  
In contrast to studies aiming to establish the role of genistein in homeostasis, the 
experiments designed for identification of gene expression profiles associated with a 
therapy, are often carried with suprapharmacological concentrations of a drug. In several 
studies of this kind, the most of affected genes were not dependent on hormonal regulation 
(Farivar et al., 2003; Lavigne et al., 2008; Li & Sarkar, 2002). The genes repeatedly found to be 
down regulated by genistein, were those involved mainly in signal transduction, 
oncogenesis, cell proliferation, protein phosphorylation and transcription. On the other 
hand, genistein up-regulated genes were related mainly to signal transduction, protein 
dephosphorylation, heat shock response, inactivation of mitogen-activated protein kinase 
(MAPK), apoptosis and cell cycle arrest. Among the genes regulated by genistein there was 
a number of genes regulated by tyrosine kinases inhibitors, like Gleevec (STI-571), 
lavendustin and herbimycin (Farivar et al., 2003). Studies on the evaluation of the global 
transcript profile changes performed on different models could be a valuable approach to 
determine the similarity in the mode of action of genistein derivatives, comparing to a 
parent compound. This approach may be useful for description of potential “druggable” 
targets and determination the safety profile of new compounds.  
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3. Synthetic derivatives of genistein and their potential medicinal 
applications  
Many opportunities for derivatization of genistein, apparent from its structural formula 
encourage the synthesis of derivatives with improved pharmacological profile. The chemical 
basis describing functionalization of three phenolic groups at C-5, C-7 and C-4’ in typical O-
acylation or O-alkylation reactions and skeletal modifications of genistein core, involving C–
C bond formation is reviewed elsewhere (Rusin et al., 2010). Multiple examples of 
promising candidates intended to be used in therapy of different diseases are listed below. 
Among the diseases potentially treatable with the genistein derivatives are cancer, 
osteoporosis and metabolic disorders. Other suggested applications of genistein derivatives 
cover antibacterial and antiparasitic treatment. It must be noted, however, that most of 
presented derivatives have the status of experimental or investigational drugs. 
3.1 Genistein derivatives for treatment of osteoporosis 
Hormonal replacement therapy with synthetic estrogens was initially used for prevention of 
osteoporosis, however serious side effects of hormone replacement therapy stimulated the 
search for therapeutics, alternative to estrogens. Currently, among agents used in 
pharmacological prevention of osteoporosis are selective estrogen receptor modulators 
(SERMs), which function mainly as the antiresorptive agents (Reginster, 2011). Genistein, as 
a potential antiosteoporotic dietary supplement draw attention for many years, mostly on 
the basis of epidemiological observations (Knight & Eden, 1996; Messina, 1995). Moreover, 
genistein was reckoned as a safe supplement, because it did not produce the harmful, 
estrogen-like effects in the uterus. However, the overall conclusions of genistein 
supplementation and retardation of bone loss are ambiguous. The randomized, double-
blind, and placebo-controlled study by Marini et al. (2007) in osteopenic postmenopausal 
women revealed decreased bone resorption and increased bone formation in the genistein 
group. However, the results of this study permit only the conclusion that genistein may 
prevent progress from the mild disease - osteopenia, to its severe form – osteoporosis. Thus, 
genistein can be effective rather in chemoprevention than treatment of this disease. 
For a long period of time the synthetic isoflavone, ipriflavone (7-isopropoxyisoflavone) was 
an attractive candidate for a bone-building agent, due to its anabolic, but not estrogenic 
activity (Gennari, 1997). Ipriflavone inhibits bone resorption mediated by osteoclasts and 
stimulates activity of osteoblast in cell cultures and in experimental models of osteoporosis 
in vivo. However, clinical studies shown no statistically significant difference in annual 
percentage change from baseline lumbar spine and bone mineral density between those 
given ipriflavone and those given calcium (Alexandersen at al., 2001). 
In the matter of fact, there is no universal drug for osteoporosis and new treatments, 
comprising of both new drugs and new drug combinations are still under clinical 
investigations. Side effects of currently used drugs, which are their obvious drawbacks, 
accounts for directing attention to phytoestrogens such as isoflavones and their derivatives 
as more reliable drugs.  
Genistein modification aiming enhancement of its antiosteoporetic properties is presented 
by Wang et al. (2005), who synthesized a number of genistein derivatives in which the C-7 or 
C-4’ hydroxyl groups were variously substituted. Among seventeen novel genistein 
derivatives the authors found five, which shown increased antiosteoporetic activity when 
compared to genistein, no acute toxicity and no stimulation of endometrium proliferation in 
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mouse model of osteoporosis. The derivatives inhibiting bone loss during estrogen shortage 
contained the 2-hydroxyetylthio motif, which the authors assumed to be a key 
pharmacophore. The best results were observed for 4’,5,7-tri[3-(2-hydroxyetylthio)propoxy] 
isoflavone.  
Useful information on the structural features of genistein derivatives related to 
antiosteopotic effects may be drown from the work of Zhang et al. (2008b). They discovered 
two natural derivatives of genistein in the stem bark of Erythrina variegata L.: 8-
prenylgenistein and 6,8-diprenylgenistein stimulating osteoblastic proliferation, 
differentiation and mineralization in UMR 106 cells. These derivatives caused significant 
increase of alkaline phosphatase in cells treated by either 8-prenylgenistein or 6,8-
diprenylgenistein for 48 h at the concentration of 10-10 M. A structure-activity relationship 
study indicates that prenylation at of genistein at C-8, but not at C-6, may increase its bone-
protective effect. 
Wang et al. (2007) presented the strategy, combining nitric oxide and genistein cooperation 
in inhibiting of a bone loss. The NO donor drugs effectively counteract bone mass loss 
occurring due to reduced rate of estrogen biosynthesis in postmenopausal women 
(Wimalawansa, 2000). What is particularly important, the NO donors not only slow down 
the rate of bone resorption, but also stimulate proliferation of osteoclasts (Hukkanen et al., 
2003). In order to find a bifunctional derivative of genistein having both estrogenic 
properties and being an effective nitric oxide donor Wang et al. (2007) synthesized genistein 
7,4’-(nitroxy) butyrate. Its NO-releasing capacity was studied in vitro using immature 
osteoblastic cell line MC3T3-E1 cells. It has been demonstrated that NO is released from the 
derivative less rapidly and for a longer time than from glyceryl trinitrate (GTN), the classical 
NO donor, routinely used in medical treatment (Wang et al., 2007). Using MTT assay and 
flow cytometry it was determined that the compound stimulated growth of MC3T3-E1 cells 
in a dose- and time-dependent manner, albeit the stimulation was weaker than that 
observed for an optimal concentration of estradiol. The measurements of the activity of a 
bone-specific isoform of alkaline phosphatase and the expression of osteocalcin, a specific 
marker for late osteoblast differentiation, as well as the rate of formation of calcific 
deposition revealed that the derivative stimulated osteoclast differentiation and 
mineralization more effectively than genistein, glyceryl trinitrate or combination of the two.  
3.2 Genistein derivatives and hypertension 
Genistein has been suggested to be protective in cardiovascular diseases. The study in vivo 
on spontaneously hypertensive rats had shown, that genistein reduced systolic blood 
pressure and enhanced endothelium-dependent aortic relaxation (Vera et al., 2007). 
Genistein reduced endothelial dysfunction due to increased endothelial nitric oxide 
synthase (eNOS) activity, associated with increased calmodulin-1 expression and decreased 
superoxide generation. Nitric oxide (NO) produced by eNOS is a well-known regulatory 
molecule involved in the modulation of contractility of vasculature thus maintaining 
vascular homeostasis (Miller & Megson, 2007). 
Matsumoto et al. (2005) synthesized bifunctional derivative of genistein, which was aimed 
to inhibit tyrosine kinases, implicated in development of a hypertension, and release 
nitrogen oxide to enhance the effect. The authors synthesized two novel genistein 
derivatives 7-[(4-nitroxy)butyroyl]-genistein and 7-[(4nitrooxymethyl)-(alfa-
methyl)phenylpropanyl]-genistein, and assessed their ability to relax rat endothelium-
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denuded aortic strips. Both derivatives and genistein itself induced aortic relaxation in the 
following order:  7-[(4nitrooxymethyl)-(alfa-methyl)phenylpropanoyl]-genistein > 7-[(4-
nitroxy)butyroyl]-genistein > genistein. The relaxation induced by the tested genistein 
derivatives was abolished by a guanylyl cyclase inhibitor, which proved, that genistein 
derivatives indeed acted as NO donors.  
3.3 Genistein and its derivatives for treatment of cystic fibrosis  
Genistein was shown to partially activate the defective chloride channels (cystic fibrosis 
transmembrane regulator, CFTR) associated with cystic fibrosis (CF). Genistein not only 
partially restored the CFTR activity but also augmented CFTR maturation and increased its 
localization at the cell surface (reviewed by Węgrzyn et al., 2010). Pre-clinical studies with 
genistein have provided a basis for clinical trials with CF patients, and a Phase II clinical 
study is currently underway. So far, genistein derivatives for potential treatment of cystic 
fibrosis have not been studied extensively. Galietta et al. (2001) generated a combinatorial 
compound library based on two lead compounds, flavones and benzo[c]quinoliziniums, 
which activate CFTR Cl2- conductance by direct interaction with the CFTR molecule. Among 
several novel derivatives they identified compounds with high potency to activate CFTR, 
7,8-benzoflavones, containing features of both flavones and benzo[c]-quinoliziniums.  
3.4 Derivatives with antimicrobial and antiparasitic activity   
Antimicrobial properties of genistein are described in many papers, although the exact 
mechanism of this activity remains largely unknown (Hong et al., 2006; Ulanowska et al., 
2006; Verdrengh et al., 2004). Cell survival studies suggest that genistein is a bacteriostatic, 
rather than a bactericidal agent (Ulanowska et al., 2007). There is a suggestion that 
antibacterial properties of genistein may be mediated by the stabilization of the covalent 
topoisomerase II-DNA cleavage complex (Verdrengh et al., 2004). The concentration of 
genistein necessary for bacterial growth retardation depends on the strain, but is regarded 
as relatively high (100 M).  
Zhang et al. (2008a) reported the derivatization of genistein leading to an increased 
antibacterial and antifungal activity. They prepared three series of derivatives in which the 
genistein ring system was linked to the heterocyclic moieties with 2-carbon, 3-carbon or 4-
carbon spacers. Among these compounds, five exhibited good antibacterial activities, while 
one of them also showed notable antifungal activity. The activity of the mentioned 
derivatives was several fold higher than that of genistein.  
The antimicrobial activity of genistein derivatives was also described by Li et al. (2008). 
They synthesized and tested 14 new deoxybenzoin derivatives of genistein and found that 
dimeric forms were generally more active than genistein or deoxybenzoins against selected 
microorganisms.  
Several genistein derivatives are indicated for treatment of parasitic diseases. The potential 
use of genistein derivatives for anti-protozoan therapies were reported by Gargala et al. 
(2005) and Stachulsky et al. (2006), and, for anti-helminthic treatment by Naguleswaran et al. 
(2006). Gargala et al. (2005) screened fifty-two dihydroxyisoflavone and 
trihydroxydeoxybenzoin derivatives for their influence on protozoan parasites life cycle: 
Neospora caninum, Sarcocystis neurona and Cryptosporidium parvum. Two agents selected in 
this screening: 3’-bromo and 4’-bromo genistein were tested as in Cryptosporidium parvum-
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infected immunosuppressed gerbils. It was found, that these compounds more effectively 
abolished fecal microscopic oocyst shedding than two routinely used drugs, nitazoxanide 
and paromomycin.  
Some of genistein derivatives described previously by Gargala (2005) were tested for 
inhibitory effects on the larval development of tapeworms Echinococcus sp. (Naguleswaran et 
al., 2006). The study shown, that 2’-bromo- and 6’-bromo genistein induced considerable 
damage in E. granulosus protoscolex. The above mentioned genistein derivatives are safe in 
terms of side effects caused by the estrogen receptor stimulation, because they do not bind 
to ER. These derivatives were shown to be selective for parasites, without antibacterial 
activity (Stachulsky et al., 2006), what allows to avoid the development of resistant bacterial 
strains.  
3.5 Derivatives of genistein designed for anti-cancer therapy 
Several strategies of genistein modification were applied in order to put its anticancer 
potential in use. Among them are targeted therapy and chemical modification of a molecule, 
so that to improve the interaction with molecular targets. Examples of those modifications 
are described below. 
3.5.1 Targeting genistein to cancer cells by conjugation with antibodies or peptide 
ligands  
Major strategy of targeted therapy is to construct two-domain drugs, in which one domain 
recognizes the target cells, whereas the other one exerts a therapeutic activity. In order to 
selectively target genistein to intra-cellular kinase domain of epidermal growth factor 
receptor (EGFR) Uckun et al. (1998) obtained a conjugate of genistein with epidermal 
growth factor (EGF) via photochemical cross-linking. This conjugate was intended to target 
cancer cells overexpressing the epidermal growth factor receptor (EGFR). It was expected, 
that internalization of the conjugate should increase the intracellular concentration of 
genistein, and lead to efficient inhibition of the EGFR tyrosine kinase activity. In vitro 
studies confirmed strong proapoptotic activity of a conjugate in human breast cancer cells. 
(Uckun et al., 1998). Moreover SCID mice bearing tumors of human breast cancer cells 
(MDA-MB-231), treated intraperitoneally with the conjugate at 100 ug/day for 10 days 
showed significantly better survival as compared to mice treated with adriamycin, 
cyclophosphamide or methotrexate (Uckun et al., 1998).  
A similar genistein targeting strategy, based on expected local increase of genistein 
concentration, was used for experimental treatment of leukemias (Ek et al., 1998). Genistein 
was conjugated to B43 antibody, recognizing the CD19 antigen, present on the surface of B 
lymphocytes and absent from plasma cells. CD19 is an adaptor protein for Lyn tyrosine kinase, 
amplifying signals transduction from nonreceptor Src tyrosine kinases. The study was 
performed on SCID mice bearing human acute lymphoblastic leukemia (ALL) or non-
Hodkin’s lymphoma shown the conjugate to be more therapeutically effective than cytostatics 
routinely used for treatment of this kind of leukemias (Ek et al., 1998). In subsequent in vivo 
study performed on cynomolgus monkeys the conjugate administered intravenously shown 
no toxicity during long term observation (Messinger et al., 1998). These highly encouraging 
results inclined the authors to perform phase I clinical study (Uckun et al. 1999). The pilot 
study of B43-genistein in 15 patients with refractory B-lineage acute lymphoblastic leukemia 
shown that the conjugate was well tolerated by all patients with no life-threatening side 
effects. There was one durable complete remission and two transient responses.  
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More recently, Gentile et al. (2003) used genistein-monoclonal antibody approach to treat 
SW-620 and HT-29 colon cancer cells. The conjugate of genistein and 17.1A monoclonal 
antibody recognizing an epithelial membrane antigen expressed in colon cancer 
significantly inhibited cell growth in vitro and in vivo, and induced apoptosis.  
3.5.2 Genistein as a vector selectively targeting cytostatic drugs to ER positive 
cancers 
Interesting therapeutic approach is the use of genistein as a carrier, delivering drugs to cells 
expressing target recognized by this isoflavonoid. However, some difficulties must be 
overcome: (1) cytotoxic agent in a conjugate must not produce a loss of genistein binding to 
the target protein, (2) the target of a cytotoxic agent should be present in the subcellular 
structure which is likely to be achievable by a carrier, (3) the concentration of the receptor 
should be high, and its expression should not be down-regulated by a carrier. 
An example of the above mentioned strategy was the use of genistein derivative, 6-
carboxymethylgenistein (6CG) as a potential vector of a cytostatic drug, daunomycin to 
estrogen receptor expressing cells (Somjen et al., 2002; Somjen et al, 2003). Although the 
relative binding affinity of 6-CG was 0.1% to ERb and 0.01% to ERa, respectively as 
compared to the estradiol, it was shown that 6-CG activated the receptor, which 
translocated to the nucleus. Transactivation studies proved that 6-CG is a ligand of ERs. In 
the absence of estradiol 6-CG was found to be an agonist, while in the presence of estradiol 
it shown moderate antagonist activity for ERa (Somjen et al., 2003). The cytotoxicity of this 
conjugate was tested against H295R cells. At low daunomycin concentration (0.3-3nM) the 
cytotoxicity of a conjugate was 10 times higher than that of free drug, what indicated 
successful targeting of a conjugate. At higher concentration (30nM) the differences were less 
profound, and no differences were observed between daunomycin and its conjugate with 6-
CG, what indicates that the toxicity was a result of non-specific, high intracellular 
concentration of daunamycin. The targeting of daunomycin conjugated to 6-CG via ER was 
also confirmed by the experiment with cells devoid of ER, where no differences in toxicity of 
a conjugate and free daunomycin were observed (Somjen et al., 2003). 
3.5.3 Genistein derivatives designed for treatment of hormone dependent cancers 
Endocrine treatment with selective estrogen-receptor modulators (SERMs), such as 
tamoxifen and raloxifene is of major therapeutic value in patients with estrogen-receptor 
positive tumors. Hormone-dependent breast cancer tumors contain estrogen receptors and 
tumor growth depends on estrogens. Tamoxifen, a partial nonsteroidal estrogen agonist, is a 
competitive inhibitor of estradiol, and the prototype of SERMs. However, after long 
exposure to the tamoxifen the resistance often develops, so designing and synthesis of new 
antiestrogens for treatment of breast cancer is of much importance.  
Very promising trisubstituted derivatives of genistein able to bind estrogen receptor with 
low affinity were recently described by Davis et al. (2008). Several compounds were able to 
inhibit cell proliferation in a dose-dependent manner, and compounds containing the bulky 
7-phenylmethoxy substituent were toxic for both hormone-dependant MCF-7 cells and 
hormone-independent MDA-MB-231 cells. Thus, the synthetic tri-substituted isoflavones act 
on multiple signaling pathways leading to activation of mechanisms of cell-death and 
ultimately affecting survival of breast cancer cells. A novel genistein derivative exhibiting 
significantly higher antiproliferative activity than the parent drug was recently obtained by 
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Kohen et al., (2007) by attaching an N-tert-butoxycarbonylo-1,6-diamino-hexane group to C2 
of genistein. Although this novel genistein derivative did not show estrogenic activity, its 
antiproliferative activity was different in estrogen-sensitive cancer cell lines expressing ERǂ 
and ERǃ mRNA at different ratios. The highest antiproliferative effect measured by 
radioactive thymidine incorporation was observed for an estrogen-sensitive colon cancer 
cell line (320DM), and the lowest for an ovarian cancer cell line (A2780). Interestingly, the 
genistein derivative was more toxic for cells that preferentially expressed mRNA for ERǃ, 
relative to ERǂ.  
3.5.4 High-throughput screening of genistein derivatives  
In recent years a search for anticancer cytostatics based on the synthesis of libraries of 
differently substituted derivatives of genistein, followed by high-throughput screening in 
vitro has been intensified. Although it looks, to some extent, like trusting in serendipity, it 
allows to empirically find the most promising drug candidates. 
Such screening of more than 350 genistein analogues allowed to find several putative drugs  
for clinical development (Novogen). Among them was isoflaven phenoxodiol, which has been 
granted fast track status from the FDA to facilitate its development as a therapy for recurrent 
ovarian and prostate cancers (Silasi et al., 2009). Other compounds: triphendiol, NV-143 and 
NV-128, which are further derivatives of phenoxodiol, are still investigational drugs. 
Phenoxodiol was intended for usage in a therapy of early-stage prostate cancer, late-stage, 
hormone-refractory prostate cancer, early stage cervical and vaginal cancer, chemo-resistant 
and chemo-refractory ovarian cancer. It was shown to induce death of cancer cells through 
plejotropic mechanism: inhibition of the anti-apoptotic proteins FLIP and IAP and the 
increase of the pro-apoptotic protein BAX, inhibition of tyrosine kinases and topoisomerase 
II in a dose-dependent manner (Alvero et al., 2006; Kluger et al., 2007; Constantinou et al., 
2002, Sapi et al., 2004]. Phenoxodiol was tested in phase 3 OVATURE trial in women with 
recurrent ovarian cancer. No statistically significant improvement in its primary 
(progression-free survival) or secondary (overall survival) endpoints were found, so the 
study was terminated (Howes et al., 2011).  
Triphendiol is tested for use against pancreas and bile duct cancers and found to act 
synergistically with gemcitabine (Saif et al,. 2009). NV-143 was found to be effective against 
multiple melanoma cell lines, while NV-128, demonstrated efficacy in monotherapy and as a 
chemosensitizer in non-small cell lung carcinoma (NSCLC) cell lines. Interestingly, NV-128 
induced cell death via a caspase-independent pathway and autophagic cell death (Alvero et 
al., 2009). In summary, triphendiol, NV-143 and NV-128 exhibited a good safety profile, they 
were well tolerated and non-clastogenic. Effective inhibition of tumor proliferation was 
shown in animal models after oral administration of the tested drugs. 
3.5.5 Synthetic glycoconjugates of genistein interacting with mitotic spindle  
The effectiveness of microtubule-targeting drugs for the treatment of a broad range of 
human cancers has been shown in many clinical studies. The search for compounds with 
similar mechanisms of action to taxanes or vinca alkaloids resulted in the discovery of a 
number of novel microtubule-targeting drugs, the majority of which are natural products.  
Although, genistein was recently shown to interact with interphase microtubules 
(Mukherjee et al., 2010), its clinical use as an antimitotic drug is rather doubtful due to very 
high concentration necessary to achieve this effect. However, it seems that chemical 
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derivatization can help to obtain novel compounds exhibiting increased affinity to 
microtubules. We found, among the glycosidic derivatives described by Polkowski et al. 
(2004), that the compound named G21 (Fig. 6), which inhibited cell proliferation at the 
concentration 10 times lower than genistein, interacted with mitotic spindle (Rusin et al., 
2009).  
This compound caused remarkable mitotic block at the concentration inhibiting cell 
proliferation by half, compared to the control. Our observations were recently confirmed by 
others (Ahmed et al., 2011). Earlier studies shown that the structure of G21 molecule was 
stable, it did not hydrolyze under in vitro cell culture conditions (Ksycińska et al., 2004) and 
its toxicity against cancer cells was higher than against normal ones (Popiołkiewicz et al., 
2005). The continuation of our work on glyconjugates of genistein exhibiting antimitotic 
activity pointed another molecule, called Ram3 (Fig. 6), as a potent agent affecting mitotic 
spindle (Rusin et al., 2011) and leading to apoptotic cell death. 
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Fig. 6. Structure of genistein glycoconjugates showing antimitotic activity. A. G21, B. Ram3.  
4. Conclusion 
Many studies concerning the biological properties of genistein analogues demonstrated that 
the modification of the parent isoflavone may lead to compounds exhibiting not only 
enhancement of the activities already known, but also revealed novel properties, not 
observed for the parent compound. The biological activity of the synthetic derivatives of 
genistein, briefly summarized in this review, indicate that, at least some of them can be 
viewed as important lead compounds for further modifications. Although most of the 
derivatives have the status of investigational or experimental drugs, multiple identified 
molecular targets of genistein identified so far give hope that clinically applicable and 
target-specific genistein derivatives may appear in the future.   
There are obviously open questions, which diseases such genistein derivatives would be 
addressed for and whether they would be therapeutically useful in monotherapy or - what 
seems more probable - in combination therapies.  
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